55
Views
1
CrossRef citations to date
0
Altmetric
Menopause

Coronary heart disease and HRT in France: MISSION study prospective phase results

, , , , &
Pages 696-700 | Received 25 Aug 2008, Accepted 05 Sep 2008, Published online: 07 Jul 2009
 

Abstract

Objective. To determine the morbidity incidence associated with Hormone Replacement Therapy (HRTs) in postmenopausal women. This paper presents the results concerning the incidence of coronary heart disease (CHD).

Design. MISSION study started on 5 January 2004, the cutoff for data collection was June 2006 (follow-up no. 1). ‘Exposed group’: postmenopausal women currently on HRT, commonly prescribed in France or stopped ≤5 years previously. ‘Unexposed group’: never received HRT or stopped >5 years previously.

Results. Data were available for 4949 patients (without CHD at the beginning of the follow-up): 2693 Exposed group and 2256 Unexposed group. The incidence during follow-up no. 1 of postmenopausal CHD was not significantly different in the Exposed group (0.11%) compared with the Unexposed group (0.13%). In the Exposed group the time between start of HRT and menopause was 2.93 ± 4.46 years in those who experienced CHD and 1.53 ± 3.20 years in those who had no incidence of CHD (p = 0.3).

Conclusion. In the MISSION cohort, no increased risk of CHD was found in the Exposed group compared with the Unexposed group

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.